Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment.
Bastian L, Hartmann AM, Beder T, Hänzelmann S, Kässens J, Bultmann M, Hoeppner MP, Franzenburg S, Wittig M, Franke A, Nagel I, Spielmann M, Reimer N, Busch H, Schwartz S, Steffen B, Viardot A, Döhner K, Kondakci M, Wulf G, Wendelin K, Renzelmann A, Kiani A, Trautmann H, Neumann M, Gökbuget N, Brüggemann M, Baldus CD. Bastian L, et al. Among authors: viardot a. Leukemia. 2022 Jun;36(6):1676-1680. doi: 10.1038/s41375-022-01557-6. Epub 2022 Apr 9. Leukemia. 2022. PMID: 35397658 Free PMC article. No abstract available.
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N, Basara N, Baurmann H, Beck J, Brüggemann M, Diedrich H, Güldenzoph B, Hartung G, Horst HA, Hüttmann A, Kobbe G, Naumann R, Ratei R, Reichle A, Serve H, Stelljes M, Viardot A, Wattad M, Hoelzer D. Gökbuget N, et al. Among authors: viardot a. Blood. 2011 Sep 29;118(13):3504-11. doi: 10.1182/blood-2011-01-329441. Epub 2011 Jun 28. Blood. 2011. PMID: 21715318 Free article. Clinical Trial.
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.
Gökbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Hüttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Gökbuget N, et al. Among authors: viardot a. Blood. 2012 Sep 6;120(10):2032-41. doi: 10.1182/blood-2011-12-399287. Epub 2012 Apr 4. Blood. 2012. PMID: 22493293 Free article. Clinical Trial.
Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.
Burmeister T, Bartels G, Gröger D, Trautmann H, Schwartz S, Lenz K, Tietze-Bürger C, Viardot A, Wäsch R, Horst HA, Reinhardt R, Gökbuget N, Hoelzer D, Kneba M, Brüggemann M. Burmeister T, et al. Among authors: viardot a. Haematologica. 2014 Feb;99(2):e23-5. doi: 10.3324/haematol.2013.090720. Haematologica. 2014. PMID: 24497567 Free PMC article. Clinical Trial. No abstract available.
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Zugmaier G, Gökbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, Horst HA, Marks R, Faul C, Diedrich H, Reichle A, Brüggemann M, Holland C, Schmidt M, Einsele H, Bargou RC, Topp MS. Zugmaier G, et al. Among authors: viardot a. Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19. Blood. 2015. PMID: 26480933 Free PMC article.
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, Burmeister T, Wessiepe D, Topp MS, Bargou R. Gökbuget N, et al. Among authors: viardot a. Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12. Haematologica. 2017. PMID: 28082340 Free PMC article. Clinical Trial. No abstract available.
Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.
Kobitzsch B, Gökbuget N, Schwartz S, Reinhardt R, Brüggemann M, Viardot A, Wäsch R, Starck M, Thiel E, Hoelzer D, Burmeister T. Kobitzsch B, et al. Among authors: viardot a. Haematologica. 2017 Oct;102(10):1739-1747. doi: 10.3324/haematol.2016.161273. Epub 2017 Jul 27. Haematologica. 2017. PMID: 28751559 Free PMC article.
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Wilhelm C, Pezzutto A, Zijlstra JM, Neste EVD, Lugtenburg PJ, Doorduijn JK, Gelder MV, van Imhoff GW, Zettl F, Braulke F, Nickelsen M, Glass B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N, Trümper L; ACT-2 study investigators. Wulf GG, et al. Among authors: viardot a. Leukemia. 2021 Jan;35(1):143-155. doi: 10.1038/s41375-020-0838-5. Epub 2020 May 7. Leukemia. 2021. PMID: 32382083 Clinical Trial.
129 results